ID   OSW
AC   CVCL_0B19
SY   Oswald
DR   GEO; GSM1974798
DR   Wikidata; Q54936727
RX   Patent=US7897150;
RX   PubMed=17532464;
RX   PubMed=21908323;
RX   PubMed=23365669;
RX   PubMed=26842912;
RX   PubMed=27197945;
RX   PubMed=27257868;
RX   PubMed=29674676;
RX   PubMed=31175136;
CC   Group: Patented cell line.
CC   Part of: FACC canine tumor cell line panel.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9116.
CC   Doubling time: 16 hours (PubMed=27257868).
CC   Sequence variation: Mutation; VGNC; 38196; ASXL1; Simple; p.Gly618fs (c.1850dupG); Zygosity=Heterozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; 40797; FBXW7; Simple; p.Arg694Gln (c.2081G>A); Zygosity=Heterozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; 42490; KMT2C; Simple; p.Gly976fs (c.2922delG); Zygosity=Heterozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; 42491; KMT2D; Simple; p.Gln5395fs (c.16183delC); Zygosity=Homozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; 43761; NF1; Simple; p.Asn58fs (c.167delA); Zygosity=Homozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; 44567; PTEN; Simple; p.Lys245fs (c.734delA); Zygosity=Homozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; -; SPEN; Simple; p.Ala8fs (c.13_14insG); Zygosity=Heterozygous (PubMed=31175136).
CC   Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Arg164His (c.491G>A); Zygosity=Heterozygous (PubMed=31175136).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Breed/subspecies: Airedale Terrier.
ST   Source(s): PubMed=27197945; PubMed=31175136
ST   Dog FHC2010: 235,239
ST   Dog FHC2054: 151,156
ST   Dog FHC2079: 279
ST   Dog PEZ1: 115,123
ST   Dog PEZ3: 119,136
ST   Dog PEZ5: 103
ST   Dog PEZ6: 176,183
ST   Dog PEZ8: 240
ST   Dog PEZ12: 270,288
ST   Dog PEZ20: 180
DI   NCIt; C128121; Canine lymphoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Male
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 21-03-23; Version: 13
//
RX   Patent=US7897150;
RA   Kisseberth W.C.;
RT   "Canine lymphoma cell line and uses thereof.";
RL   Patent number US7897150, 01-Mar-2011.
//
RX   PubMed=17532464; DOI=10.1016/j.leukres.2007.04.003;
RA   Kisseberth W.C., Nadella M.V.P., Breen M., Thomas R., Duke S.E.,
RA   Murahari S., Kosarek C.E., Vernau W., Avery A.C., Burkhard M.J.,
RA   Rosol T.J.;
RT   "A novel canine lymphoma cell line: a translational and comparative
RT   model for lymphoma research.";
RL   Leuk. Res. 31:1709-1720(2007).
//
RX   PubMed=21908323; DOI=10.1177/1040638711408064;
RA   O'Donoghue L.E., Rivest J.P., Duval D.L.;
RT   "Polymerase chain reaction-based species verification and
RT   microsatellite analysis for canine cell line validation.";
RL   J. Vet. Diagn. Invest. 23:780-785(2011).
//
RX   PubMed=23365669; DOI=10.1371/journal.pone.0054464;
RA   Wells J.W., Evans C.H., Scott M.C., Rutgen B.C., O'Brien T.D.,
RA   Modiano J.F., Cvetkovic G., Tepic S.;
RT   "Arginase treatment prevents the recovery of canine lymphoma and
RT   osteosarcoma cells resistant to the toxic effects of prolonged
RT   arginine deprivation.";
RL   PLoS ONE 8:E54464-E54464(2013).
//
RX   PubMed=26842912; DOI=10.1111/vco.12197;
RA   Hartley G., Faulhaber E.A., Caldwell A., Coy J., Kurihara J.N.,
RA   Guth A., Regan D.P., Dow S.W.;
RT   "Immune regulation of canine tumour and macrophage PD-L1 expression.";
RL   Vet. Comp. Oncol. 15:534-549(2017).
//
RX   PubMed=27197945; DOI=10.1111/vco.12192;
RA   Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.;
RT   "The Flint Animal Cancer Center (FACC) canine tumour cell line panel:
RT   a resource for veterinary drug discovery, comparative oncology and
RT   translational medicine.";
RL   Vet. Comp. Oncol. 15:481-492(2017).
//
RX   PubMed=27257868; DOI=10.1371/journal.pone.0156689;
RA   Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.;
RT   "Intrinsic radiosensitivity and cellular characterization of 27 canine
RT   cancer cell lines.";
RL   PLoS ONE 11:E0156689-E0156689(2016).
//
RX   PubMed=29674676; DOI=10.1038/s41598-018-23207-7;
RA   Taher L., Beck J., Liu W., Roolf C., Soller J.T., Rutgen B.C.,
RA   Hammer S.E., Chodisetti M., Sender S., Sterenczak K.A., Fuellen G.,
RA   Junghanss C., Brenig B., Nolte I., Schutz E., Murua Escobar H.;
RT   "Comparative high-resolution transcriptome sequencing of lymphoma cell
RT   lines and de novo lymphomas reveals cell-line-specific pathway
RT   dysregulation.";
RL   Sci. Rep. 8:6279-6279(2018).
//
RX   PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346;
RA   Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.;
RT   "Identifying candidate druggable targets in canine cancer cell lines
RT   using whole exome sequencing.";
RL   Mol. Cancer Ther. 18:1460-1471(2019).
//